Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 4NIH 3NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 5Sarcoma 1Other hematologic neoplasm 1Myeloid 1Dermatologic 1Classical hematology 1

Conditions

Melanoma 1

Interventions

Interferon-alpha 6Radiosurgery 4Dacarbazine 4encorafenib 3binimetinib 3aldesleukin 3Radiotherapy 3Methotrexate 3Immunohistochemistry 3Gene Expression Profiling 3Filgrastim 3Etoposide 3Cyclophosphamide 3Cisplatin 3Watchful Waiting 2Vincristine 2Vinblastine 2Temozolomide 2Polymerase Chain Reaction 2Nivolumab 2Ipilimumab 2Introns 2Interferon alpha-2 2Immunologic Techniques 2Flow Cytometry 2Carboplatin 2trametinib 1tebentafusp 1sulforaphane 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Colony-Stimulating Factors × Dermatologic × Clear all
NCT00071981 2023-06-28

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Eastern Cooperative Oncology Group

Phase 2 Completed
175 enrolled 12 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡